- Stocks
- Healthcare
- NASDAQ: SUPN

Price (delayed)

$33.62

Market cap

$1.83B

P/E Ratio

35.02

Dividend/share

N/A

EPS

$0.96

Enterprise value

$1.89B

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for

Supernus Pharmaceuticals's revenue has increased by 11% YoY

The gross profit is up by 10% YoY

The stock's price to earnings (P/E) is 68% more than its 5-year quarterly average of 20.8 but 2.5% less than its last 4 quarters average of 35.9

The quick ratio has contracted by 34% YoY but it has grown by 16% from the previous quarter

The EPS has declined by 31% year-on-year and by 15% since the previous quarter

The company's net income fell by 29% YoY and by 14% QoQ

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.supernus.com

What are the main financial stats of SUPN

Market
Valuations
Earnings

Shares outstanding

54.48M

Market cap

$1.83B

Enterprise value

$1.89B

Price to earnings (P/E)

35.02

Price to book (P/B)

2

Price to sales (P/S)

2.73

EV/EBIT

30.59

EV/EBITDA

12.88

EV/Sales

2.82

Revenue

$668.5M

EBIT

$61.67M

EBITDA

$146.45M

Free cash flow

$161.81M

Per share
Balance sheet
Liquidity

EPS

$0.96

Free cash flow per share

$2.98

Book value per share

$16.77

Revenue per share

$12.29

TBVPS

$18.25

Total assets

$1.79B

Total liabilities

$879.66M

Debt

$517.37M

Equity

$912.15M

Working capital

$151.8M

Debt to equity

0.57

Current ratio

1.21

Quick ratio

1.06

Net debt/EBITDA

0.38

Margins
Efficiency
Dividend

EBITDA margin

21.9%

Gross margin

86.1%

Net margin

7.8%

Operating margin

7.4%

Return on assets

3%

Return on equity

6%

Return on invested capital

14.7%

Return on capital employed

5.8%

Return on sales

9.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Supernus Pharmaceuticals stock price performed over time

Intraday

0.24%

1 week

-4.73%

1 month

-8.52%

1 year

22.48%

YTD

-5.75%

QTD

-7.2%

How have Supernus Pharmaceuticals's revenue and profit performed over time

Revenue

$668.5M

Gross profit

$575.75M

Operating income

$49.33M

Net income

$52.04M

Gross margin

86.1%

Net margin

7.8%

The company's operating margin fell by 40% YoY but it rose by 7% QoQ

The net margin is down by 36% year-on-year and by 14% since the previous quarter

SUPN's operating income is down by 34% YoY but it is up by 7% from the previous quarter

The company's net income fell by 29% YoY and by 14% QoQ

What is Supernus Pharmaceuticals's growth rate over time

What is Supernus Pharmaceuticals stock price valuation

P/E

35.02

P/B

2

P/S

2.73

EV/EBIT

30.59

EV/EBITDA

12.88

EV/Sales

2.82

The stock's price to earnings (P/E) is 68% more than its 5-year quarterly average of 20.8 but 2.5% less than its last 4 quarters average of 35.9

The EPS has declined by 31% year-on-year and by 15% since the previous quarter

SUPN's price to book (P/B) is 26% less than its 5-year quarterly average of 2.7 and 4.8% less than its last 4 quarters average of 2.1

Supernus Pharmaceuticals's equity has increased by 10% YoY and by 2.9% QoQ

The P/S is 22% below the 5-year quarterly average of 3.5 and 2.5% below the last 4 quarters average of 2.8

Supernus Pharmaceuticals's revenue has increased by 11% YoY

How efficient is Supernus Pharmaceuticals business performance

The return on sales has declined by 43% year-on-year and by 10% since the previous quarter

SUPN's return on invested capital is up by 39% year-on-year and by 17% since the previous quarter

The company's return on equity fell by 34% YoY and by 15% QoQ

The return on assets has declined by 33% year-on-year and by 17% since the previous quarter

What is SUPN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SUPN.

How did Supernus Pharmaceuticals financials performed over time

Supernus Pharmaceuticals's total assets is 104% higher than its total liabilities

SUPN's current ratio is down by 40% year-on-year but it is up by 13% since the previous quarter

The quick ratio has contracted by 34% YoY but it has grown by 16% from the previous quarter

The debt is 43% smaller than the equity

The debt is up by 18% since the previous quarter and by 18% year-on-year

Supernus Pharmaceuticals's debt to equity has increased by 16% from the previous quarter and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.